Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jan 12, 2024
TickeronGET DAILY SIGNALS
Smart Investing: $TLRY Rakes in +strong performance via Automated Trading.

Smart Investing: $TLRY Rakes in +strong performance via Automated Trading.

Artificial intelligence-powered trading robots have been making waves, demonstrating their capabilities in the volatile world of finance. At "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," these AI-driven bots successfully generated a remarkable +strong performance while trading TLRY over the previous week. In this article, we delve into the technical analysis of TLRY's recent performance, focusing on key indicators, earnings results, market capitalization, and notable price and volume movements within the Pharmaceuticals: Other Industry.

Technical Indicator Insights: TLRY's RSI Oscillator

One notable technical signal for TLRY is the movement of its 10-day Relative Strength Index (RSI) Oscillator. On December 29, 2023, the RSI moved out of the overbought zone, suggesting a potential shift from an upward to a downward trend. According to Tickeron's A.I.dvisor, in 15 out of 16 instances where the RSI exited the overbought zone, the stock moved lower in the subsequent days. This statistical pattern places the odds of a downward move at a substantial 90%. Traders are advised to consider selling the stock or exploring put options in response to this signal.

Earnings Report Overview: January 09, 2024

TLRY's latest earnings report, dated January 09, 2024, revealed earnings per share of -7 cents, falling short of the estimated -5 cents. The company, with 12.73 million shares outstanding, currently holds a market capitalization of 1.29 billion. Analyzing the earnings miss and its impact on the stock's valuation provides valuable insights for investors considering their positions in TLRY.

Market Capitalization Comparison in Pharmaceuticals: Other Industry

Comparing TLRY's market capitalization with industry peers is crucial for understanding its relative standing. In the Pharmaceuticals: Other Industry, the average market capitalization is 2.79 billion, with a range spanning from 246 million (PEMTF) to a staggering 82.08 billion (ZTS). TLRY's position within this spectrum influences its attractiveness to investors and potential for future growth.

Price Movement Metrics: Highs, Lows, and Industry Averages

Analyzing TLRY's price movements alongside industry benchmarks provides context for evaluating its performance. The average weekly, monthly, and quarterly price growth across all stocks in the Pharmaceuticals: Other Industry stands at 0%, 34%, and 21%, respectively. TLRY's individual price trajectory becomes more apparent when compared to its industry counterparts, offering insights into its relative strength and weaknesses.

Notable high and low price movements within the industry further highlight TLRY's performance. With UPC experiencing the highest price growth at 66%, and CNGGF witnessing a significant fall at -52%, understanding these extremes aids in contextualizing TLRY's own price dynamics.

Volume Trends in Pharmaceuticals: Other Industry

Examining TLRY's trading volume alongside industry trends is essential for assessing investor sentiment. The average weekly, monthly, and quarterly volume growth across all stocks in the Pharmaceuticals: Other Industry is -3%, 34%, and -17%, respectively. TLRY's volume trends, compared to industry averages, provide valuable insights into the level of interest and activity surrounding the stock.

In summary, the technical analysis of TLRY's recent performance, encompassing indicators, earnings results, market capitalization, price movements, and volume trends, offers investors a comprehensive understanding of the stock's current position and potential future trajectory.

Related Ticker: TLRY

Contributor

Dem Sem's AvatarDem Sem|Expert

Momentum Indicator for TLRY turns negative, indicating new downward trend

TLRY saw its Momentum Indicator move below the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 72 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.222) is normal, around the industry mean (8.029). P/E Ratio (-2.339) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.32B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 2%. BHC experienced the highest price growth at 26%, while UPC experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 51%. For the same stocks of the Industry, the average monthly volume growth was 14% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 58
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.